New drug cocktail aims to save lungs in scleroderma patients

NCT ID NCT06297096

Recruiting now Disease control Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining two drugs, nintedanib and tocilizumab, works better than standard treatments (like mycophenolate) for people with systemic sclerosis (scleroderma) who also have lung scarring. The trial will enroll 86 adults and follow them for 56 weeks, measuring lung function and imaging changes. The goal is to slow down lung damage and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nintedanib and tocilizumab combination
What this could lead to: If successful, this combination could offer a more effective treatment option to slow lung damage in people with systemic sclerosis and interstitial lung disease.
What could go wrong: This is a relatively small Phase 3 trial (86 people), and the combination may cause side effects like diarrhea or liver issues. It is not a cure, and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Centrum Wsparcia Badań Klinicznych
RECRUITING

Warsaw, Masovian Voivodeship, 02-637, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.